Peter F Thall (Peter Thall)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 33

Top Venues

Clinical trials (London, England)

Nature medicine

Pharmaceutical statistics

Statistical methods in medical research

Florida State University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Florida State University Sep 01 1971 - Aug 31 1975

United States

PHD :: Statistics

Publications

David Marin, Ye Li, Rafet Basar, Hind Rafei, May Daher, Jinzhuang Dou, Vakul Mohanty, Merve Dede, Yago Nieto, Nadima Uprety, Sunil Acharya, Enli Liu, Jeffrey Wilson, Pinaki Banerjee, Homer A Macapinlac, Christina Ganesh, Peter F Thall, Roland L Bassett, Mariam Ammari, Sheetal Rao, Kai Cao, Mayra Shanley, Mecit Kaplan, Chitra Hosing, Partow Kebriaei, Loretta J Nastoupil, Christopher R Flowers, Sadie Mae Moseley, Paul Lin, Sonny Ang, Uday R Popat, Muzaffar H Qazilbash, Richard E Champlin, Ken Chen, Elizabeth J Shpall, Katayoun Rezvani
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial. Nature medicine 30 (3) (2024)
David Marin, Ye Li, Rafet Basar, Hind Rafei, May Daher, Jinzhuang Dou, Vakul Mohanty, Merve Dede, Yago Nieto, Nadima Uprety, Sunil Acharya, Enli Liu, Jeffrey Wilson, Pinaki Banerjee, Homer A Macapinlac, Christina Ganesh, Peter F Thall, Roland L Bassett, Mariam Ammari, Sheetal Rao, Kai Cao, Mayra Shanley, Mecit Kaplan, Chitra Hosing, Partow Kebriaei, Loretta J Nastoupil, Christopher R Flowers, Sadie Mae Moseley, Paul Lin, Sonny Ang, Uday R Popat, Muzaffar H Qazilbash, Richard E Champlin, Ken Chen, Elizabeth J Shpall, Katayoun Rezvani
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial. Nature medicine (2024)
David Marin, Ye Li, Rafet Basar, Hind Rafei, May Daher, Jinzhuang Dou, Vakul Mohanty, Merve Dede, Yago Nieto, Nadima Uprety, Sunil Acharya, Enli Liu, Jeffrey Wilson, Pinaki Banerjee, Homer A Macapinlac, Christina Ganesh, Peter F Thall, Roland L Bassett, Mariam Ammari, Sheetal Rao, Kai Cao, Mayra Shanley, Mecit Kaplan, Chitra Hosing, Partow Kebriaei, Loretta J Nastoupil, Christopher R Flowers, Sadie Mae Moseley, Paul Lin, Sonny Ang, Uday R Popat, Muzaffar H Qazilbash, Richard E Champlin, Ken Chen, Elizabeth J Shpall, Katayoun Rezvani
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial. Nature medicine 30 (3) (2024)
David Marin, Ye Li, Rafet Basar, Hind Rafei, May Daher, Jinzhuang Dou, Vakul Mohanty, Merve Dede, Yago Nieto, Nadima Uprety, Sunil Acharya, Enli Liu, Jeffrey Wilson, Pinaki Banerjee, Homer A Macapinlac, Christina Ganesh, Peter F Thall, Roland L Bassett, Mariam Ammari, Sheetal Rao, Kai Cao, Mayra Shanley, Mecit Kaplan, Chitra Hosing, Partow Kebriaei, Loretta J Nastoupil, Christopher R Flowers, Sadie Mae Moseley, Paul Lin, Sonny Ang, Uday R Popat, Muzaffar H Qazilbash, Richard E Champlin, Ken Chen, Elizabeth J Shpall, Katayoun Rezvani
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial. Nature medicine (2024)
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus. Clinical trials (London, England) 21 (3) (2024)
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus. Clinical trials (London, England) 21 (3) (2024)
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus. Clinical trials (London, England) 21 (3) (2024)
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstrations's oncology center of excellence project optimus. Clinical trials (London, England) (2024)
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus. Clinical trials (London, England) 21 (3) (2024)
David Marin, Ye Li, Rafet Basar, Hind Rafei, May Daher, Jinzhuang Dou, Vakul Mohanty, Merve Dede, Yago Nieto, Nadima Uprety, Sunil Acharya, Enli Liu, Jeffrey Wilson, Pinaki Banerjee, Homer A Macapinlac, Christina Ganesh, Peter F Thall, Roland L Bassett, Mariam Ammari, Sheetal Rao, Kai Cao, Mayra Shanley, Mecit Kaplan, Chitra Hosing, Partow Kebriaei, Loretta J Nastoupil, Christopher R Flowers, Sadie Mae Moseley, Paul Lin, Sonny Ang, Uday R Popat, Muzaffar H Qazilbash, Richard E Champlin, Ken Chen, Elizabeth J Shpall, Katayoun Rezvani
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial. Nature medicine (2024)
David Marin, Ye Li, Rafet Basar, Hind Rafei, May Daher, Jinzhuang Dou, Vakul Mohanty, Merve Dede, Yago Nieto, Nadima Uprety, Sunil Acharya, Enli Liu, Jeffrey Wilson, Pinaki Banerjee, Homer A Macapinlac, Christina Ganesh, Peter F Thall, Roland L Bassett, Mariam Ammari, Sheetal Rao, Kai Cao, Mayra Shanley, Mecit Kaplan, Chitra Hosing, Partow Kebriaei, Loretta J Nastoupil, Christopher R Flowers, Sadie Mae Moseley, Paul Lin, Sonny Ang, Uday R Popat, Muzaffar H Qazilbash, Richard E Champlin, Ken Chen, Elizabeth J Shpall, Katayoun Rezvani
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial. Nature medicine 30 (3) (2024)
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus. Clinical trials (London, England) 21 (3) (2024)
David Marin, Ye Li, Rafet Basar, Hind Rafei, May Daher, Jinzhuang Dou, Vakul Mohanty, Merve Dede, Yago Nieto, Nadima Uprety, Sunil Acharya, Enli Liu, Jeffrey Wilson, Pinaki Banerjee, Homer A Macapinlac, Christina Ganesh, Peter F Thall, Roland L Bassett, Mariam Ammari, Sheetal Rao, Kai Cao, Mayra Shanley, Mecit Kaplan, Chitra Hosing, Partow Kebriaei, Loretta J Nastoupil, Christopher R Flowers, Sadie Mae Moseley, Paul Lin, Sonny Ang, Uday R Popat, Muzaffar H Qazilbash, Richard E Champlin, Ken Chen, Elizabeth J Shpall, Katayoun Rezvani
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial. Nature medicine 30 (3) (2024)
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstrations's Oncology Center of Excellence Project Optimus. Clinical trials (London, England) (2024)
David Marin, Ye Li, Rafet Basar, Hind Rafei, May Daher, Jinzhuang Dou, Vakul Mohanty, Merve Dede, Yago Nieto, Nadima Uprety, Sunil Acharya, Enli Liu, Jeffrey Wilson, Pinaki Banerjee, Homer A Macapinlac, Christina Ganesh, Peter F Thall, Roland L Bassett, Mariam Ammari, Sheetal Rao, Kai Cao, Mayra Shanley, Mecit Kaplan, Chitra Hosing, Partow Kebriaei, Loretta J Nastoupil, Christopher R Flowers, Sadie Mae Moseley, Paul Lin, Sonny Ang, Uday R Popat, Muzaffar H Qazilbash, Richard E Champlin, Ken Chen, Elizabeth J Shpall, Katayoun Rezvani
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial. Nature medicine 30 (3) (2024)
David Marin, Ye Li, Rafet Basar, Hind Rafei, May Daher, Jinzhuang Dou, Vakul Mohanty, Merve Dede, Yago Nieto, Nadima Uprety, Sunil Acharya, Enli Liu, Jeffrey Wilson, Pinaki Banerjee, Homer A Macapinlac, Christina Ganesh, Peter F Thall, Roland L Bassett, Mariam Ammari, Sheetal Rao, Kai Cao, Mayra Shanley, Mecit Kaplan, Chitra Hosing, Partow Kebriaei, Loretta J Nastoupil, Christopher R Flowers, Sadie Mae Moseley, Paul Lin, Sonny Ang, Uday R Popat, Muzaffar H Qazilbash, Richard E Champlin, Ken Chen, Elizabeth J Shpall, Katayoun Rezvani
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial. Nature medicine (2024)
Pavlos Msaouel, Juhee Lee, Peter F Thall
Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clinical trials (London, England) 21 (3) (2023)
Peter F Thall, Yong Zang, Ying Yuan
Generalized phase I-II designs to increase long term therapeutic success rate. Pharmaceutical statistics (2023)
Pavlos Msaouel, Juhee Lee, Peter F Thall
Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clinical trials (London, England) 21 (3) (2023)
Peter F Thall, Yong Zang, Andrew Genius Chapple, Ying Yuan, Ruitao Lin, David Marin, Pavlos Msaouel
Novel clinical trial designs with dose optimization to improve long-term outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Pavlos Msaouel, Juhee Lee, Peter F Thall
Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clinical trials (London, England) 21 (3) (2023)
Pavlos Msaouel, Juhee Lee, Peter F Thall
Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clinical trials (London, England) 21 (3) (2023)
Pavlos Msaouel, Juhee Lee, Peter F Thall
Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clinical trials (London, England) (2023)
Pavlos Msaouel, Juhee Lee, Peter F Thall
Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clinical trials (London, England) (2023)
Pavlos Msaouel, Juhee Lee, Peter F Thall
Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clinical trials (London, England) (2023)
Yun Qing, Peter F Thall, Ying Yuan
A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint. Pharmaceutical statistics (2022)
Juhee Lee, Peter F Thall, Pavlos Msaouel
Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity. Biometrics (2022)
Yeonhee Park, Suyu Liu, Peter F Thall, Ying Yuan
Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics (2021)
Liyun Jiang, Fangrong Yan, Peter F Thall, Xuelin Huang
Comparing Bayesian early stopping boundaries for phase II clinical trials. Pharmaceutical statistics 19 (6) (2020)
Sandrine Boulet, Moreno Ursino, Peter F Thall, Bruno Landi, Céline Lepère, Simon Pernot, Anita Burgun, Julien Taieb, Aziz Zaanan, Sarah Zohar, Anne-Sophie Jannot
Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. Statistical methods in medical research 29 (2) (2019)
Andrew Genius Chapple, Peter F Thall
Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination. Pharmaceutical statistics 17 (6) (2018)
Peter F Thall, Peter Mueller, Yanxun Xu, Michele Guindani
Bayesian nonparametric statistics: A new toolkit for discovery in cancer research. Pharmaceutical statistics 16 (6) (2017)
Peter F Thall, Moreno Ursino, Véronique Baudouin, Corinne Alberti, Sarah Zohar
Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. Statistical methods in medical research 28 (2) (2017)

Peter F Thall.css-eqlu8i{font-size:small;padding-left:4px;} (Peter Thall)

Publication Activity (10 Years)

Top Topics

Top Venues

Peter F Thall (Peter Thall)